{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:04:44Z","timestamp":1785539084198,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Australian Government Research Training Programme Scholarship for PhD students"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>We report the 20-year experience of the largest Australian unit performing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer and reflect on learning opportunities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective review of all cases of CRS for ovarian cancer at St George Peritonectomy Unit from Jan 1998 to Jan 2018 was performed. Prospectively collected data include age, stage, histology, disease extent (PCI), completeness of cytoreduction (CC score), HIPEC regime, 30-day surgical morbidity, disease recurrence, and death. Survival was computed using Kaplan\u2013Meier method and analysed using log-rank tests and Cox-proportional hazards models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty-one women with advanced ovarian cancer (11 primary stage III\/IV, 30 recurrent) underwent CRS, 29 (71%) with HIPEC. Most (68%) had high-volume disease (PCI\u2009&gt;\u200915). In 98%, CC0\/CC1 (residual\u2009&lt;\u20092.5\u00a0mm) was achieved. Fourteen (34%) had grade 3\/4 complications, 1 patient (2%) died within 30\u00a0days and 2 patients (5%) died within 90\u00a0days. Progression-free and median overall survival was 30.0 and 67.0\u00a0months for primary cancer, and 6.7 and 18.1\u00a0months for recurrent cancer. Survival was associated with platinum-sensitivity, PCI\u2009\u2264\u200915, and CC score 0, but not HIPEC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study reports outcomes for patients with advanced ovarian cancer patients treated in an Australian centre offering CRS and HIPEC. Whilst survival and morbidity outcomes were good for primary disease, they were poorer than predicted from the literature for cases of recurrent disease. The incorporation of evidence-based predictors of survival and multidisciplinary input are essential to achieve the best survival outcomes.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12893-022-01786-7","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T15:02:37Z","timestamp":1662994957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20\u00a0years\u2019 experience"],"prefix":"10.1186","volume":"22","author":[{"given":"R.","family":"Farrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. S.","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"1786_CR1","unstructured":"Australian Institute of Health and Welfare 2017. Cancer in Australia 2017. Cancer series no.101. Cat. no. CAN 100. Canberra: AIHW."},{"issue":"5","key":"1786_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5694\/mja14.00132","volume":"201","author":"S Anuradha","year":"2014","unstructured":"Anuradha S, Webb PM, Jordan SJ, et al. Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. Med J Aust. 2014;201(5):283\u20138.","journal-title":"Med J Aust"},{"key":"1786_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007565.pub2","author":"A Elattar","year":"2011","unstructured":"Elattar A, Bryant A, Naik R, et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011. https:\/\/doi.org\/10.1002\/14651858.CD007565.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1786_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","volume":"130","author":"SJ Chang","year":"2013","unstructured":"Chang SJ, Hodeib M, Bristow RE, et al. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013;130:493\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1786_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tjog.2016.04.010","volume":"55","author":"R Berretta","year":"2016","unstructured":"Berretta R, Marchesi F, Volpi L, et al. Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer: clinical and functional outcome. Taiwan J Obstet Gynecol. 2016;55(3):346\u201350.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"1786_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ygyno.2005.08.027","volume":"100","author":"GD Aletti","year":"2006","unstructured":"Aletti GD, Dowdy S, Podratz KC, et al. Surgical treatment of diaphragm disease correlated with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006;100:283\u20137.","journal-title":"Gynecol Oncol"},{"key":"1786_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","volume":"121","author":"P Harter","year":"2011","unstructured":"Harter P, Muallem ZM, Buhrmann C, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121:615\u20139.","journal-title":"Gynecol Oncol"},{"key":"1786_CR8","doi-asserted-by":"publisher","unstructured":"Harter P, Sehouli J, Vergote G et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Eng J Med 2021;385:2123\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2103294.","DOI":"10.1056\/NEJMoa2103294"},{"key":"1786_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos N, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381:1929\u201339.","journal-title":"N Engl J Med"},{"key":"1786_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","volume":"22","author":"T Shi","year":"2021","unstructured":"Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:439\u201349. https:\/\/doi.org\/10.1016\/S1470-2045(21)00006-1.","journal-title":"Lancet Oncol"},{"key":"1786_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340.","journal-title":"N Engl J Med"},{"key":"1786_CR12","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ejso.2015.08.172","volume":"41","author":"YR Huo","year":"2015","unstructured":"Huo YR, Liauw WS, Morris DL, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41:1578\u201389.","journal-title":"Eur J Surg Oncol"},{"key":"1786_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00605","author":"O Zivanovic","year":"2021","unstructured":"Zivanovic O, Chi DS, Zhou Q, et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK Team ovary phase II study. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.21.00605.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1786_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, Makuuchi M, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187\u201396.","journal-title":"Ann Surg"},{"key":"1786_CR15","unstructured":"Milne P, Paul T, Reid M, et al. NSW peritonectomy services planning prepared for NSW Ministry for Health. NSW Dept Health. 2015."},{"key":"1786_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/IGC.0000000000001247","volume":"28","author":"R Farrell","year":"2018","unstructured":"Farrell R, Liauw WS, Brand AH. Ovarian cancer surgery in Australia and New Zealand, A survey to determine changes in surgical practice over 10 years. Int J Gynecol Cancer. 2018;28:945\u201350.","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"1786_CR17","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","volume":"33","author":"D Tewari","year":"2015","unstructured":"Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2015;33(13):1460\u20136. https:\/\/doi.org\/10.1200\/JCO.2014.55.9898.","journal-title":"J Clin Oncol"},{"key":"1786_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/ajo.12665","volume":"57","author":"JL Nicklin","year":"2017","unstructured":"Nicklin JL, McGrath S, Obermair A, et al. The shift toward neo-adjuvant chemotherapy and interval debulking surgey for management of advanced ovarian and related cancers in a population-based setting: impact on clinical outcomes. Aust NZJ Obstet Gynaecol. 2017;57:651\u20138.","journal-title":"Aust NZJ Obstet Gynaecol"},{"key":"1786_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.semcancer.2021.02.009","volume":"77","author":"M Petrillo","year":"2021","unstructured":"Petrillo M, Sozzi G, Dessole M, et al. The role of surgery in platnum-resistant ovarian cancer: a call to the scientific community. Sem Cancer Biol. 2021;77:194\u2013202.","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"1786_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejso.2019.05.006","volume":"47","author":"SN Koole","year":"2021","unstructured":"Koole SN, Kieffer JM, Sikorska K, et al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. Eur J Surg Oncol. 2021;47(1):101\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2019.05.006.","journal-title":"Eur J Surg Oncol"},{"key":"1786_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0143","author":"MC Lim","year":"2022","unstructured":"Lim MC, Chang SJ, Park B, et al. Survival after hyperthermic intraperitoeal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer. A randomized clinical trial. JAMA Surg. 2022. https:\/\/doi.org\/10.1001\/jamasurg.2022.0143.","journal-title":"JAMA Surg"},{"key":"1786_CR22","doi-asserted-by":"crossref","unstructured":"Farrell R, Burling M, Lee YC et al., on behalf of the HyNOVA protocol steering committee. Clinical Trial Protocol for HyNOVA: hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer. ANZGOG1901\/2020). ACTRN12621000269831p (Accepted for publishing in J Gynecol Oncol. August 2021).","DOI":"10.3802\/jgo.2022.33.e1"},{"issue":"5","key":"1786_CR23","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570\u20135. https:\/\/doi.org\/10.1245\/s10434-014-4157-9.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1786_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/IGC.0000000000000864","volume":"27","author":"P Harter","year":"2017","unstructured":"Harter P, Reuss A, Sehouli J, et al. Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al. Int J Gynecol Cancer. 2017;27(2):246\u20137. https:\/\/doi.org\/10.1097\/IGC.0000000000000864.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1786_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2010.09.010","volume":"120","author":"GD Aletti","year":"2011","unstructured":"Aletti GD, Eisenhauer EL, Santillan A, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120(1):23\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2010.09.010.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1786_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ygyno.2015.04.037","volume":"138","author":"S Patankar","year":"2015","unstructured":"Patankar S, Burke WM, Wright JD, et al. Risk stratification and outcomes of women undergoing surgery for ovarian cancer. Gynecol Oncol. 2015;138(1):62\u20139.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1786_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00404-020-05684-2","volume":"302","author":"G Sozzi","year":"2020","unstructured":"Sozzi G, Petrillo M, Berretta R, et al. Incidence, predictors and clinical outcome of pancreatic fistula in patients receiving splenectomy for advanced or recurrent ovarian cancer: a large multicentric experience. Arch Gynecol Obstet. 2020;302(3):707\u201314.","journal-title":"Arch Gynecol Obstet"},{"issue":"10","key":"1786_CR28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353.","journal-title":"N Engl J Med"},{"issue":"9990","key":"1786_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015;386(9990):249\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(14)62223.","journal-title":"The Lancet"},{"issue":"64","key":"1786_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"2016","author":"T Onda","year":"1990","unstructured":"Onda T, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer Oxf Engl. 1990;2016(64):22\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2016.05.017.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"1786_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","volume":"59","author":"A Fagotti","year":"2016","unstructured":"Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer Oxf Engl. 2016;59:22\u201333. https:\/\/doi.org\/10.1016\/j.ejca.2016.01.017.","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"8","key":"1786_CR32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","volume":"29","author":"A Reuss","year":"2019","unstructured":"Reuss A, du Bois A, Harter P, et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7). Int J Gynecol Cancer. 2019;29(8):1327\u201331. https:\/\/doi.org\/10.1136\/ijgc-2019-000682.","journal-title":"Int J Gynecol Cancer"},{"key":"1786_CR33","doi-asserted-by":"publisher","first-page":"CD009786","DOI":"10.1002\/14651858.CD009786.pub3","volume":"3","author":"R van de Vrie","year":"2019","unstructured":"van de Vrie R, Rutten MJ, Asseler JD, et al. Laparoscopy for diagnosing resectibility of disease in women with advanced ovarian cancer. Cochrane Datab Syst Rev. 2019;3:CD009786. https:\/\/doi.org\/10.1002\/14651858.CD009786.pub3.","journal-title":"Cochrane Datab Syst Rev"},{"issue":"6","key":"1786_CR34","doi-asserted-by":"publisher","first-page":"613.e1","DOI":"10.1200\/JCO.2016.69.2962","volume":"35","author":"MJ Rutten","year":"2017","unstructured":"Rutten MJ, van Meurs HS, van de Vrie R, et al. Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial. J Clin Oncol. 2017;35(6):613.e1-21.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1786_CR35","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1810858.","journal-title":"N Engl J Med"},{"issue":"25","key":"1786_CR36","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1909707.","journal-title":"N Engl J Med"},{"key":"1786_CR37","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402. https:\/\/doi.org\/10.1056\/NEJMoa1910962.","journal-title":"N Engl J Med"},{"issue":"25","key":"1786_CR38","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1911361.","journal-title":"N Engl J Med"},{"issue":"22","key":"1786_CR39","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1611310.","journal-title":"N Engl J Med"},{"issue":"10106","key":"1786_CR40","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;390(10106):1949\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(17)32440-6.","journal-title":"The Lancet"},{"issue":"9","key":"1786_CR41","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469.","journal-title":"Lancet Oncol"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-022-01786-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12893-022-01786-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-022-01786-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T13:26:43Z","timestamp":1664976403000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/s12893-022-01786-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1786"],"URL":"https:\/\/doi.org\/10.1186\/s12893-022-01786-7","relation":{},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted using an appropriate consent process and ethics process. All experimental protocols were approved by the South East Sydney Local Health District Human Research Ethics Committee (HREC 18\/067) and St George Hospital (SSA 18\/G\/092), and in accordance with the Helsinki Declaration (1983).All study methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all study participants and\/or their legal guardians prior to participation in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable: This study does not contain any identifiable data or images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors do not have any conflicts of interest, either\u2009 actual or potential, including financial, personal, or other relationships that would inappropriately influence this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"338"}}